Like any successful business, we continue to evolve, progress, and achieve new goals. We would like to share these changes with you, so that you are always informed about the latest news.
Munich, 12th December 2019 – ADVITOS prevails against 5 competitors at the Nordic Financial Ecosystem Forum and wins Best Investor Pitch Award
The third Nordic Financial Ecosystem Forum in Brussels is co-hosted by Nasdaq, EQT and the Nordic Securities Association. During the event European policymakers, opinion leaders as well as representatives from the financial industry and media interact on best practices and improvements to support access to capital by companies in the Nordic and Baltic region and the EU at large.
New for this year was the introduction of the Best Investor Pitch Award. Nasdaq said via its Twitter account that it doesn’t matter if you are preparing for an IPO or looking to raise capital in the private market, you need to get investor attention. Therefore, six growth companies, selected together with the European Business Angel Network, competed for the best investor pitch– with ADVITOS being the winner.
“It is essential for young companies like ADVITOS to address potential investors and to interact with them. To be honored with the Best Investor Pitch Award is a great achievement for us and will provide us with visibility to new investors,” says Catherine Schreiber, Deputy Managing Director of ADVITOS. “The display on the Nasdaq tower in Times Square in New York is another added bonus.”
Munich, 02nd December 2019 – After a final pitch contest ADVITOS takes the third place among the MedTech companies.
21 finalists in the categories MedTech, BioTech and Digital Health had been training and competing since spring 2019 to reach the finals of the European Health Catapult (EHC). The biggest pitch contest organised by EIT Health, EHC is designed to identify and accelerate promising European start-ups in the categories of Biotech, Medtech and Digital Health. The winners were announced on the evening of the 2nd December 2019, during the first day of the EIT Health Summit.
“The EIT Health Catapult provides a high-profile audience for us and we are proud that we made it to the podium”, says Assoc. Prof. Dr. med. Bernhard Kreymann, founder and CEO of ADVITOS. “The team at ADVITOS put a lot of hard work into this competition and we are very happy with such a great result.“
To view the video that shows what ADVITOS is all about and which was shown during the final pitch visit: https://youtu.be/NFQY-J0rXMw
Munich, 11th November 2019 – With a growth rate of 680 percent, the Munich-based company ADVITOS manages to reach 27th place in the Deloitte Technology Fast 50 2019.
With the Technology Fast 50 Award Deloitte annually honors the fastest-growing technology companies in the sectors of Hardware, Software, Communications, Media & Entertainment, Healthcare & Life Sciences, Environmental Technology and FinTech.
ADVITOS is the only listed MedTech company of the Technology Fast 50 Award and achieves the 27th place.
The ranking is based on the growth in sales over the last four financial years (2015 – 2018). ADVITOS was able to record a growth of 680 percent in this period. That was achieved with the commercialization of the inhouse-developed, CE-marked and worldwide patented ADVOS technology (ADVanced Organ Support) – the only therapy worldwide offering multi organ support integrated in one single device.
“We are very excited to be listed in the prestigious Deloitte Technology Fast 50 2019.”, says Assoc. Prof. Dr. med. Bernhard Kreymann, inventor of the ADVOS procedure, founder and CEO of ADVITOS GmbH. “It is a great recognition for the entire team who has worked very hard to make this happen. Further, this will give us visibility to investors and new customers which in turn will help us with further growth and the establishment of our innovative therapy in other markets.”
About ADVITOS – ADVITOS developed the CE-marked and worldwide patented ADVOS technology (ADVanced Organ Support) – the only therapy worldwide offering multi organ support integrated in one single device. ADVOS improves survival of ICU patients by simultaneously supporting all three main detoxification organs: the liver, the lung and the kidney. The solution allows fluid-based elimination of: water-soluble toxins (kidney), protein-bound toxins (liver and kidney), and CO2 (lungs). In addition, ADVOS enables treatment of acid-base disbalances through patient individual correction of the blood pH value. The ADVOS therapy is used in intensive care units at 20 leading hospitals throughout Germany and is on its way to penetrating the international market.
Munich, 06th November 2019 – Munich-based ADVITOS has been selected among 5,000 applications from 128 different countries as one of Hello Tomorrow’s Deep Tech Pioneers
The Hello Tomorrow Global Challenge is a renowned global startup competition designed specifically to address the needs of deep tech entrepreneurs across several industries. The Challenge gives scientists and deep tech entrepreneurs around the globe a platform for their research and projects, providing participants with equity-free funding, global visibility and connections with key players in the deep tech innovation network and other fellow entrepreneurs. To date, previous early-stage participants have raised more than $300 million in funding.
Having been selected among over 5,000 applications from 128 countries means that ADVITOS has been recognized as one of the most promising projects in the deep tech innovation network.
“It is an absolute honor to be endorsed as one of the best deep tech start-ups worldwide. This represents a great opportunity to build strong relationships with technology focused investors and industry leaders around the world.”, says Assoc. Prof. Dr. med. Bernhard Kreymann, Inventor of the ADVOS technology, founder and CEO of ADVITOS. “We look forward to the next step and are optimistic to reach the Global Summit in March 2020 as pitching company.”
The Hello Tomorrow Global Summit will take place on March 12th and 13th, 2020 in Paris. ADVITOS will also attend the Business and Investor Days on March 10th and 11th, 2020.
For more information about the Hello Tomorrow Global Challenge visit: https://hello-tomorrow.org/
Munich, 16th October 2019 – Munich-based ADVITOS receives €2.3m EIC Accelerator grant from the European Union and Seal of Excellence for first class innovations.
“We are very excited to receive such a prestigious and international recognition by the European Union. It is our honor to hold the Seal of Excellence for first-class innovations worth of investment in this highly competitive programme.”, says Assoc. Prof. Dr. med. Bernhard Kreymann, Inventor of the ADVOS technology, founder and CEO of ADVITOS. “The secured grant of €2.3m will be used to improve our multi organ support device in terms of ease of use, to integrate IoT for remote access and maintenance and to prepare the international expansion by increasing our marketing and communication measures in Western Europe.”
The EIC Accelerator (SME Instrument Phase 2) is part of the European Innovation Council (EIC) pilot that supports top class innovators, entrepreneurs and small companies with funding opportunities and acceleration services like coaching and support in commercialization. The focus of the EIC Accelerator’s SME Instrument Programme is on disruptive, market-creating innovations that have significant growth potential and global ambitions.
Among 2,025 proposals submitted in this year’s 3rd cut-off of the SME Instrument Phase 2 (HORIZON 2020), only 4.6% (94) were selected by the jury of experts as projects worth funding.
Munich, 02nd October 2019 – Munich-based ADVITOS is selected as a European finalist in the EIT European Health Catapult program
The European Health Catapult (EHC) is a training and competition program that boosts the development of top-notch European health start-ups through exposure to leading experts and international investors. The program is organized by EIT Health with the support of the Health Axis Europe. It is operationally run by Cap Digital and Medical Valley with support of BIORN, Medicen and a community of +20 European partners, all leaders of healthcare innovation. EHC awards the best-of-the-best business concepts in MedTech, biotech and digital health across Europe.
The EHC start-ups get on the fast track to involve in the EIT Health Community of world leading MedTech, biotech, pharma and IT companies and international class research organizations in health care as well as the EIT Health Investor Network that unites international investors (VCs, Corporate VCs, Business Angel, and Crowd Investors).
The European Health Catapult Jury evaluated our pitch as follows “ADVITOS offers a unique, innovative and efficient solution for multi-organ failure with a clear benefit for the patients and a strong advantage over the competition. The business model is reliable, the strategy for market access clear and the team looks reliable and experienced. Moreover, the entire project was presented in a professional and efficient way. The European Health Catapult is the perfect competition for this EU-grown startup.”
“We are very happy to reach the finals of the well-known European Health Catapult. The participation in the competition fosters our growth and provides exposure to potential investors that can help us with the scale-up and internationalization planned ahead”, says Assoc. Prof. Dr. med. Bernhard Kreymann, Inventor of the ADVOS technology, founder and CEO of ADVITOS GmbH. “We look forward to the EIT Health Summit in December and are optimistic to also successfully take the final step.”
The 2019 EIT Health Catapult finals will take place at the EIT health summit on 2nd of December in Paris. For more information visit: https://www.europeanhealthcatapult.eu/
Company’s ADVOS Technology Represents First System Worldwide for Advanced Multi-Organ Support
Munich, Germany, December 7, 2017 – Hepa Wash, a Munich-based manufacturer of the worldwide first
method for advanced multi-organ support, announced today its collaboration with the German Accelerator Life
Sciences (GALS) program, an initiative founded by the German Federal Ministry for Economic Affairs and Energy
(BMWi), to facilitate the company’s U.S. expansion.
The mortality rate of intensive care patients with multi-organ failure is still very high. Although dysfunctions of
the main detoxification organs, liver, lungs, and kidneys, can clearly be delineated, the failure of one organ can
affect several others. This leads to a life-threatening toxin accumulation in the body and subsequently to
progressive organ failure and death.
Hepa Wash recently introduced the innovative approach of the ADVOS (Advanced Organ Support) procedure,
which offers multi-organ support for liver, lungs, and kidneys and correction of acid-base balance disorders. The
ADVOS device represents an evolution from conventional dialysis machines, as it uses protein enriched dialysis
water instead of regular dialysis water and allows targeted manipulation of acidity of the dialysis fluid. Within
the device, the dialysis fluid is permanently reprocessed and cleared of toxins to maintain a constantly high
detoxification performance. The AVDOS procedure has already proven its capabilities in several studies and in
large university hospitals in Germany.
“We are very excited about being accepted into the GALS program. As this is a very competitive program, it
shows that our team has done great work so far. Also, highly accomplished US experts see the great potential of
our ADVOS multi-organ support to revolutionize treatment in intensive care settings and improve patient
survival,” commented Dr. Bernhard Kreymann, CEO and founder of Hepa Wash. “The U.S. market is the largest
medical technology market in the world, but it also follows its own set of rules. Therefore, it is of utmost
importance to be supported by experienced US specialists in establishing a strategy for market approval,
reimbursement, and market penetration. Hence, we very much look forward working with the GALS advisors to
analyze our US market readiness and develop our FDA and reimbursement strategy.”
“We look forward to working with Hepa Wash. The company’s ADVOS technology has enormous potential to
improve the treatment of organ-failure patients worldwide,” commented strategic project lead and GALS
mentor Michael Bogenstaetter. “I am confident that GALS can add to Hepa Wash’s success by assisting in the
continued development of the company’s U.S. strategy,” added Christoph Lengauer, CEO of the German
Accelerator Life Sciences.
Hepa Wash’s U.S. expansion will be guided by a team of GALS mentors with profound commercial and technical
expertise in the field of organ support. Additional support through GALS includes access to the vast GALS
network of medical device industry leaders, investors, and top-notch service providers.
About Hepa Wash:
Hepa Wash has established the ADVOS system, the first method in the world for extended and individualized support of the human body’s main detoxification organs: the liver, the lungs and the kidneys. The company was founded in Garching near Munich in mid-2005 by renowned nephrology and multi-organ support expert Dr. Bernhard Kreymann who had been instrumental in establishing the pervious gold standard of organ support using single-pass albumin dialysis. Building on this expertise, Hepa Wash is developing reliable treatment methods to close the therapeutic gap in multi-organ failure.
About the German Accelerator Life Sciences:
The German Accelerator Life Sciences (GALS) is an initiative of the German Federal Ministry for Economic Affairs and Energy (BMWi) with the goal of helping German startups and young companies succeed in the global marketplace. GALS, centrally located and highly connected in the world’s leading life sciences innovation hub in Cambridge, Massachusetts, offers support in multiple areas: from operational assistance to high-end strategic guidance by experienced industry experts and key opinion leaders. GALS opened its doors in October 2015 and is headquartered in Cambridge, Massachusetts.
For more information, visit: www.GermanAccelerator.com/Life-Sciences
Contact:
Hepa Wash GmbH
Julia Rochser, M.A. Marketing Manager
+49 (89) 4111842-27
marketing@hepawash.com
German Accelerator Life Sciences
Annika Pierson Head of Strategy & Operations
+1-617-531-0404 gals@germanaccelerator.com
Additional Material: For more on the functionality of the ADVOS procedure, please click: http://hepawash.com/en/funktionsweise/
PDF Download